ASCO Annual Meeting: Multiple Myeloma | Conference

Moreau discussed conclusions drawn from part 2 of the CASSIOPEIA trial and the need for further follow-up with bortezomib, thalidomide and dexamethasone plus maintenance daratumumab in newly diagnosed multiple myeloma.

During a discussion at ASCO 2021, Mounzer Agha, MD, talked about mitigation strategies used by the investigators from the CARTITUDE-2 trial to prevent cognitive and neuro-movement disorders commonly associated with CAR T-cell therapy.

Moreau detailed the patient characteristics of those enrolled on the CASSIOPEIA trial, which investigating bortezomib, thalidomide and dexamethasone plus daratumumab in patients with newly diagnosed multiple myeloma.